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ABSTRACT
Guidelines recommend high doses of b-lactams
for the therapy of endocarditis. This report des-
cribes a retrospective study of 15 endocarditis
patients (median age 64 years), treated according
to guidelines, whose b-lactam trough plasma
concentrations were measured with high-per-
formance liquid chromatography because of tol-
erance or efﬁcacy concerns. For amoxycillin, the
mean level was 86.8 mg ⁄L (range: 30–212 mg ⁄L);
ﬁve (45%) patients had concentrations > 1000·
MIC. For cloxacillin, the mean level was
47.9 mg ⁄L (range: 16.7–104 mg ⁄L). The conse-
quences of high and unpredicted b-lactam trough
plasma concentrations for a prolonged period
have not yet been thoroughly evaluated.
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High doses of b-lactams are used for the treat-
ment of endocarditis [1–3], but treatment guide-
lines do not take into account many factors related
to the host, such as age, sex and liver function,
that may affect b-lactam pharmacokinetics [3,4].
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Treatment guidelines have not changed signiﬁ-
cantly during the last four decades, although the
population of patients with endocarditis has
changed dramatically, with a mean age of
35 years in 1940 now increased to 60 years, and
a maximal incidence observed at the age of
70 years [5,6]. Elderly patients will usually
achieve higher plasma concentrations because of
pharmacokinetic changes in this population.
Moreover, high plasma concentrations of b-lac-
tams could be more toxic to the elderly, partic-
ularly with respect to the brain and kidneys [6,7].
Pontchaillou is a university-afﬁliated hospital
that serves as a referral centre for the area of
Rennes, France. A retrospective study was per-
formed of all adult patients admitted to the
infectious diseases unit between 2000 and 2002
with deﬁnite bacterial endocarditis, according to
the Duke criteria [8], for whom b-lactam trough
plasma concentrations were requested by the
physician in charge of the patient. Patient charts
were reviewed and the following data were
collected: (1) weight, sex, age and creatinine
plasma concentration at the time of admission;
(2) the MIC of the prescribed b-lactam for the
bacterium isolated from blood cultures; (3) the
antibiotics administered; and (4) the reason(s) for
determination of the b-lactam concentration.
Trough plasma levels were measured in samples
drawn immediately before the next administra-
tion of b-lactam; these were kept on ice and sent
to the pharmacology department. b-Lactam con-
centrations were determined on the same day
by high-performance liquid chromatography
(HPLC), as described previously [9]. Plasma
creatinine clearance was estimated according to
the Cockroft and Gault prediction rule [10].
Fifteen patients (12 male, three female) were
studied (Table 1). Median age was 64 years
(range 22–79 years), median weight was 65 kg,
median creatinine serum concentration was
92 lmol ⁄L, and median estimated creatinine
clearance was 69 mL ⁄min. Five patients had
baseline creatinine values > 100 lmol ⁄L. The bac-
teria isolated in blood cultures were Streptococcus
spp. (n = 5), Enterococcus faecalis (n = 5), Staphylo-
coccus aureus (n = 4) and Klebsiella oxytoca (n = 1).
b-Lactam regimens were prescribed according to
published guidelines [3,4], initially in association
with gentamicin. The MIC of the b-lactam pre-
scribed, determined in ten cases, was always
between 0.05 and 0.4 mg ⁄L. b-Lactam plasma
concentrations were measured in nine patients
because dose-related intolerance was suspected,
including renal failure occurring after the
discontinuation of aminoglycosides (n = 8)
and ⁄ or confusion (n = 3). In seven patients,
b-lactam plasma concentrations were measured
because of efﬁcacy concerns.
Amoxycillin trough plasma concentrations for
nine patients were determined on a total of 11
occasions. The mean value was 86.8 mg ⁄L, with
a wide range of 30–212 mg ⁄L (> 1000· the MIC
in ﬁve cases). Cloxacillin trough plasma concen-
trations were determined for three patients; the
mean value was 47.9 mg ⁄L (range: 16.7–
104 mg ⁄L). When tolerance was the issue,
b-lactam trough plasma concentrations were
> 40 mg ⁄L in seven of nine patients; following
a dosage reduction, there was a subsequent
improvement in tolerance. When the issue was
efﬁcacy, the determination of the b-lactam
plasma concentration was never followed by an
increased b-lactam dosage. Two patients in this
group required surgical treatment because of
uncontrolled infection: one patient with pace-
maker endocarditis caused by a methicillin-
sensitive S. aureus strain, from whom the pace-
maker was not initially removed; and one
patient with prosthetic valve endocarditis caused
by E. faecalis.
Monitoring of plasma concentrations has
already been validated for various drugs, inclu-
ding anticonvulsants, immunosuppressive treat-
ments, digoxin, theophyllin, and antibiotics such
as aminoglycosides and glycopeptides, and is
currently under evaluation for protease inhibitors.
To date, monitoring of b-lactam plasma concen-
trations during the treatment of endocarditis has
not been practiced because: (1) determination of
b-lactam concentrations was not achieved easily
until the recent development of HPLC; (2) the
optimal concentrations for treatment efﬁcacy (i.e.,
the precise plasma concentration level and the
length of time for which the concentration should
remain above the MIC) are not yet known
precisely; and (3) b-lactam agents are usually
considered to be drugs with few dose-related side
effects and a large therapeutic index.
HPLC has been developed widely during
recent years and allows the precise determination
of the concentrations of most drugs in various
body ﬂuids. It has been validated extensively, and
the results can be obtained in a few hours. The
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Table 1. Monitoring of b-lactam trough plasma concentration in 15 patients with endocarditis
Age
(years) Sex Weight (kg)
Estimated
creatinine
clearance Bacteria
MIC
(mg ⁄L)
b-Lactam
dosage
Trough
plasma
concentration
Reasons for
monitoring Evolution
54 M 76 66 mL ⁄min Streptococcus
bovis
0.06 Amoxycillin
12 g ⁄day
H36: 61 mg ⁄L
H48: 70 mg ⁄L
H72: 88 mg ⁄L
Efﬁcacy
concerns
(prosthetic
valve)
Cure
62 F 64 100 mL ⁄min Streptococcus
agalactiae
NA Amoxycillin
12 g ⁄day
212 mg ⁄L Renal
(plasma
creatinine =
425 lmol ⁄mL)
Resolution of
renal failure
after
cefotaxime
was
substituted
for
amoxycillin
51 M 59 36 mL ⁄min Klebsiella
oxytoca
0.05 Imipenem
3 g ⁄day
15 mg ⁄L Efﬁcacy
concerns
(prosthetic
valve)
Cure after
prolonged
treatment (90
days)
79 M 75 113 mL ⁄min Streptococcus
bovis
0.06 Amoxycillin
6 g ⁄day
45 mg ⁄L Confusion Improved
after dose
reduction
60 M 74 81 mL ⁄min Streptococcus
bovis
0.09 Amoxycillin
12 g ⁄day
94 mg ⁄L Renal failure
(plasma
creatinine =
168 lmol ⁄mL)
Renal failure
resolved
after dose
reduction
23 M 67 146 mL ⁄min Streptococcus
sanguis
NA Penicillin G
24 MU ⁄day
41 mg ⁄L Efﬁcacy
(prosthetic
valve)
Cure
concerns
65 M 78 72 mL ⁄min Enterococcus
faecalis
0.38 Amoxycillin
18 g ⁄day
71 mg ⁄L Efﬁcacy
concerns
(prosthetic
valve)
Relapse after
42 days of
intravenous
treatment
22 F 45 74 mL ⁄min Staphylococcus
aureus
0.38 Ceftriaxone
4 g ⁄day
32 mg ⁄L Efﬁcacy
concerns
Cure
63 M 73 74 mL ⁄min Staphylococcus
aureus
NA Cloxacillin
6 g ⁄day
23 mg ⁄L Renal failure
(plasma
creatinine =
540 lmol ⁄mL)
plus
confusion
plus
efﬁcacy
concerns
Cure
Cloxacillin
dosage
maintained
(renal
function and
neurological
status
improved)
79 M 65 59 mL ⁄min Staphylococcus
aureus
NA Cloxacillin
8 g ⁄day
104 mg ⁄L Renal
failure
(plasma
creatinine =
160 lmol ⁄mL)
Renal failure
improved
after dose
reduction
79 M 66 50 mL ⁄min Enterococcus
faecalis
0.12 Amoxycillin
6 g ⁄day
166 mg ⁄L Renal
failure
(plasma
creatinine =
659 lmol ⁄mL)
Renal failure
improved
after dose
reduction
73 M 61 56 mL ⁄min Enterococcus
faecalis
0.40 Amoxycillin
6 g ⁄day
42 mg ⁄L Renal
failure
(plasma
creatinine =
143 lmol ⁄L)
Renal failure
improved
after dose
reduction
73 M 59 9 mL ⁄min Enterococcus
faecalis
0.50 Amoxycillin
6 g ⁄day
75 mg ⁄L Renal
failure
(plasma
creatinine =
797 lmol ⁄mL)
plus
confusion
Renal
function and
neurological
status
improved
after dose
reduction
72 F 60 30 mL ⁄min Enterococcus
faecalis
0.50 Amoxycillin
6 g ⁄day
31 mg ⁄L Renal
failure
(plasma
creatinine =
143 lmol ⁄mL)
Renal failure
resolved
after dose
reduction
77 M 65 25 mL ⁄min Staphylococcus
aureus
NA Cloxacillin
6 g ⁄day
17 mg ⁄L Efﬁcacy
concerns
(pacemaker
not removed)
Relapse after
28 days of
intravenous
treatment
NA, not available.
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cost is c. 30 euros ⁄ test, and this can be reduced
further if the test is performed routinely. High
plasma concentrations of b-lactams have neuro-
logical toxicity [7]. The mental status of patients
receiving high doses of b-lactams has not been
investigated thoroughly, and the effects of the
very high b-lactam concentrations observed in the
present study could be insidious and remain
unsuspected. For example, lethargy, asthenia,
depression and anorexia are common symptoms
in elderly patients treated for endocarditis and are
investigated rarely.
The main caveat for the systematic monitor-
ing of b-lactam concentrations during treatment
of endocarditis is the lack of data on the
optimal concentrations required. Although the
correlation between very high b-lactam plasma
concentrations and toxicity (especially neurolog-
ical toxicity) is likely, it has not yet been
demonstrated formally. Likewise, even though
animal models suggest that trough plasma
b-lactam concentrations of 4· MIC are sufﬁcient,
it is not clear whether these data can be
extrapolated to humans. Although there is no
reason to increase the trough plasma b-lactam
concentrations to > 10· MIC for the treatment of
endocarditis (R. Tulkens, personal communica-
tion), the results of the present study suggest
that the use of current guidelines probably leads
to even higher concentrations in most patients,
and particularly in the elderly. The conse-
quences of these high concentrations remain to
be determined. HPLC could offer an opportun-
ity to monitor plasma b-lactam concentrations,
and would allow individualised rather than
standardised treatment. Prospective, random-
ised, multicentre studies are required to evalu-
ate the impact of such monitoring on
endocarditis therapy.
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intensive care unit
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ABSTRACT
This report describes a retrospective analysis of 33
patients admitted to an intensive care unit with
suspicion of necrotising fasciitis (NF) of the
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